Since 1999, the number of deaths caused by tetanus in the United States has not exceeded 10 in a given year. This statistic shows the number of deaths caused by tetanus in the U.S. from 1990 to 2019.

In 2022, there were around 28 cases of tetanus in the United States. The annual number of tetanus cases in the United States has decreased steadily over the past few decades, and in the years 2018 and 2019 there were no reported cases. The decrease in tetanus cases in the United States and around the world is mostly due to high rates of vaccination.

What is tetanus? Tetanus is an infection caused by bacteria that live in the environment. Spores of tetanus bacteria are often found in soil and dust and enter the body through broken skin, such as puncture wounds. Tetanus cannot be spread from one person to another. One of the most common symptoms of tetanus is a tightening of the jaw muscles, leading tetanus to often be called "lockjaw". Other symptoms include muscle spasms, muscle stiffness, trouble swallowing, seizures, headache, and fever. Like in the United States, cases of tetanus have decreased since the year 1980 for every region around the world. In 2022, there were a total of 6,651 cases of tetanus worldwide. The highest number of cases was found in Africa, however the year prior the Eastern Mediterranean reported the most cases.

Tetanus vaccination Vaccination is the best way to protect against tetanus and most cases of tetanus in the United States are among people who have not been vaccinated. There are multiple vaccinations that protect against tetanus as well as other diseases such as DTap, DT, Tdap, and Td. Tetanus vaccinations are safe and effective and recommended for people of all ages, with children receiving multiple vaccinations and adults recommended to get vaccinated every 10 years. As of 2022, around 94 percent of one-year-olds in the United States had received the recommended three doses of the combined diphtheria, tetanus toxoid, and pertussis (DTP3) vaccine.

In Spain, two deaths from tetanus were reported in 2021 after a year with one registered causality due to the disease. Figures fluctuated throughout the depicted period, reaching the highest point in 2008, when deaths from tetanus totaled five cases in the European country. Tetanus is an infectious disease caused by the clostridium tetani bacteria, producing severe muscle spam. Vaccination schemes for newborns, infants, and adults prevent the disease.

This statistic displays the number of deaths from tetanus confirmed in Europe in 2018. In this year, three deaths were reported in both Romania and the United Kingdom.

The number of cases of tetanus worldwide has decreased dramatically since 1980. This statistic shows the number of cases of tetanus reported each year from 1980 to 2023 worldwide, by region.

Project Tycho datasets contain case counts for reported disease conditions for countries around the world. The Project Tycho data curation team extracts these case counts from various reputable sources, typically from national or international health authorities, such as the US Centers for Disease Control or the World Health Organization. These original data sources include both open- and restricted-access sources. For restricted-access sources, the Project Tycho team has obtained permission for redistribution from data contributors. All datasets contain case count data that are identical to counts published in the original source and no counts have been modified in any way by the Project Tycho team. The Project Tycho team has pre-processed datasets by adding new variables, such as standard disease and location identifiers, that improve data interpretabilty. We also formatted the data into a standard data format.

Each Project Tycho dataset contains case counts for a specific condition (e.g. measles) and for a specific country (e.g. The United States). Case counts are reported per time interval. In addition to case counts, datsets include information about these counts (attributes), such as the location, age group, subpopulation, diagnostic certainty, place of aquisition, and the source from which we extracted case counts. One dataset can include many series of case count time intervals, such as "US measles cases as reported by CDC", or "US measles cases reported by WHO", or "US measles cases that originated abroad", etc.

Depending on the intended use of a dataset, we recommend a few data processing steps before analysis:

• Analyze missing data: Project Tycho datasets do not inlcude time intervals for which no case count was reported (for many datasets, time series of case counts are incomplete, due to incompleteness of source documents) and users will need to add time intervals for which no count value is available. Project Tycho datasets do include time intervals for which a case count value of zero was reported.
• Separate cumulative from non-cumulative time interval series. Case count time series in Project Tycho datasets can be "cumulative" or "fixed-intervals". Cumulative case count time series consist of overlapping case count intervals starting on the same date, but ending on different dates. For example, each interval in a cumulative count time series can start on January 1st, but end on January 7th, 14th, 21st, etc. It is common practice among public health agencies to report cases for cumulative time intervals. Case count series with fixed time intervals consist of mutually exxclusive time intervals that all start and end on different dates and all have identical length (day, week, month, year). Given the different nature of these two types of case count data, we indicated this with an attribute for each count value, named "PartOfCumulativeCountSeries".

In 2021, the mortality rate of tetanus among infants in rural China was 0.06 per 100,000. Neonatal tetanus was once a major cause of death for newborns in China and many other developing countries. This fatal disease is the result of an invasion of tetanus bacilli via the umbilical cord, which is usually caused by insufficient hygiene measures in maternity wards. With improvements to conditions in hospitals and a universal vaccine program covering all pregnant women, tetanus cases were rare in China in recent years.

Snapshot img

Tetanus Toxoid Vaccine Market Size 2024-2028

The tetanus toxoid vaccine market size is forecast to increase by USD 1.24 billion at a CAGR of 4.5% between 2023 and 2028.

The market is witnessing significant growth due to several key factors. Licensing agreements between vaccine manufacturers and governments or healthcare organizations are driving market expansion. Furthermore, the introduction of new tetanus toxoid vaccines, such as those containing additional antigens, is contributing to market growth. However, the high cost of healthcare, vaccines, and treatments for infectious diseases remains a challenge for the market, particularly in developing countries. To mitigate this, governments and non-profit organizations are implementing initiatives to increase vaccine affordability and accessibility. Overall, the market is expected to continue its growth trajectory in the coming years, with a focus on increasing vaccine accessibility and affordability to combat infectious diseases.

What will be the Size of the Tetanus Toxoid Vaccine Market During the Forecast Period?

Request Free Sample

The market encompasses the production and distribution of vaccines designed to prevent Tetanus and in some cases, Diphtheria. These vaccines are essential medicines In the global public health landscape, protecting against vaccine-preventable diseases. Tetanus, a bacterial infection causing severe muscle stiffness and spasms, can lead to life-threatening complications. The market includes Diphtheria-Tetanus-Pertussis (DTP) and Tetanus-Diphtheria (TD) vaccines, as well as more recent combinations like the Tetanus, Diphtheria, and Pertussis (Tdap) vaccine. Vaccination schedules recommend these vaccines for childhood immunization, asylum seekers, and pregnant women, among others. Tetanus Toxoid, a key component of these vaccines, stimulates the production of immunity against Tetanus.
Vaccine development continues, with ongoing clinical investigations into new formulations and dosage recommendations. Immunogenicity, safety, and efficacy are crucial considerations In the development process. The market's growth is driven by the ongoing commitment to preventing Tetanus and other vaccine-preventable diseases.

How is this Tetanus Toxoid Vaccine Industry segmented and which is the largest segment?

The tetanus toxoid vaccine industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Age Group

  Neonatals
  Adults


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France


  Asia



  Rest of World (ROW)

By Age Group Insights

The neonatals segment is estimated to witness significant growth during the forecast period.

Tetanus is a bacterial infection causing muscle stiffness and spasms, with neonatal tetanus being a particular concern, affecting newborns through contaminated umbilical stumps or nonsterile delivery instruments. Vaccines, including Tetanus Toxoid, Diphtheria-Tetanus-Pertussis (DTaP), and Tetanus and Diphtheria, play a crucial role in preventing tetanus. Vaccine development involves clinical investigation and rigorous testing for efficacy and safety. Hospitals and clinics administer these vaccines, following immunization schedules for children and adults. Vaccines are essential medicines in publicly funded programs, and their availability is critical in reducing disease burden. Booster doses and immunity maintenance are essential for long-term protection. Tetanus toxoid vaccine manufacturing adheres to stringent standards to ensure safety and efficacy.

Vaccines prevent various vaccine-preventable diseases, including diphtheria, pertussis, hepatitis B, poliomyelitis, and tuberculosis. Immunization is a vital public health intervention to protect individuals and communities.

Get a glance at the market report of share of various segments Request Free Sample

The Neonatals segment was valued at USD 3.39 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 44% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

The market in North America holds a significant share due to increased adoption, comprehensive end-user coverage, and the presence of major market players like Pfizer Inc., Merck & Co. Inc., and GlaxoSmithKline Plc. In the US, tetanus cases are rare, with approximately 30 reported annually according to the National Notifiable Disease Surveillance System (NNDSS) of the Centers for Disease Control and Preventio

Tetanus data sources and citations. (XLS 114Â kb)

In 2019, Ghana registered 176 total deaths due to tetanus, decreasing slightly from the previous year. The number of deaths was higher in 2000, as it reached roughly 460 deaths. The death cases kept a downward trend since 2000, reaching the lowest in 2019. Tetanus is non-transmissible and infects cuts and wounds.

BackgroundMaternal tetanus toxoid (MTT) vaccination during pregnancy remains an important factor for reducing infant mortality globally, especially in developing nations, including Bangladesh. Despite commendable progress in reducing child mortality through widespread MTT vaccination during pregnancy, the issue still exists. This analysis explores the impact of MTT vaccination on neonatal mortality in Bangladesh and identifies associated factors.MethodsThis research utilizes data from the 2019 Bangladesh Multiple Indicator Cluster Survey (MICS). The dataset consists of 23,402 cases; among them, 587 cases resulted in infant death. The outcome variable was infant mortality, which was binary. The independent variables identified as potential contributors to the cause of death included tetanus toxoid vaccination status, mode of delivery (cesarean section or not), and mother’s education level, among others. The Poisson model was employed to analyze the data.ResultsThe analyses showed that the neonatal mortality rate was 2.51%. Notably, 45.90% of mothers received the MTT vaccination during pregnancy. Among them, 23.07% received a single dose, and 22.82% took adequate doses (receiving more than two doses) and adhered to WHO guidelines. The adjusted incidence rate ratio (IRR) was 1.36, which indicates that there was a 36% higher risk of neonatal mortality for those children whose mothers did not take TT (IRR = 1.36, p = 0.081). We also found that women from middle-class households (IRR = 1.58, 95% CI = 0.98, 2.54) and women with higher parity (IRR = 1.96, 95% CI = 0.95, 4.03) also had a higher risk of newborn fatalities. A comparable trend has been observed regarding the correlation between the number of tetanus doses administered and neonatal mortality, where it also emphasizes the importance of receiving adequate doses (a minimum of 2 doses of tetanus vaccine) to mitigate neonatal mortality (adjusted IRR = 0.54, 95% CI = 0.29, 1.01) in comparison to no doses received.ConclusionAdministering a minimum of one maternal tetanus dose significantly lowers the risk of neonatal mortality. Other than Maternal Tetanus Toxoid vaccination, the analyses underscore various contributors to neonatal mortality, encompassing maternal healthcare, delivery procedures, socio-economic status, and education. Targeted interventions addressing these factors have the potential to efficiently decrease neonatal mortality rates and improve overall maternal and child health.

The row-wise proportional distribution across various categories.

This statistic shows the number of deaths globally due to lack of vaccination, by disease. In 2002, 213,000 people died of tetanus worldwide.

Multivariate analysis of community and socio-economic factors associated with neonatal, postnatal and child mortality in Bangladesh (2004–2011).

In 2022, there were around five cases of tetanus reported in Canada, while in 1993 around 10 cases were reported. This statistic depicts the number of tetanus cases that occurred in Canada from 1957 to 2022, by year.

The death rate in Malaysia decreased by 0.6 deaths per 1,000 inhabitants (-9.95 percent) in 2022 in comparison to the previous year. Nevertheless, the last two years recorded a significantly higher death rate than the preceding years.The crude death rate refers to the number of deaths in a given year, expressed per 1,000 population. When studied in combination with the crude birth rate, the rate of natural population increase can be determined.Find more statistics on other topics about Malaysia with key insights such as share of children aged 12-23 months immunized against diphtheria, pertussis and tetanus (DPT), female smoking rate, and health expenditure as a share of gross domestic product.

In Ethiopia, neonatal mortality has been declined since the declaration of Millennium Developmental Goals, but the rate was slower since 2006. Thus, this study was designed to assess the determinants of neonatal mortality (NM) in North Shoa Zone. A community based case-control study was conducted on 84 cases and 252 controls. Cases were deceased new-borns within 28 days of birth while controls were infants survived beyond the first 28 days. Data were collected from mothers of the cases and controls using interviewer administered questionnaires. Multivariate analysis was done to examine determinants of NM. Variables significantly associated with NM in bivariate analysis were selected for multivariate analysis. Neonates whose mothers not attended antenatal care (AOR: 3.47; 95%CI: 1.44–8.32), delivered at home (AOR: 2.86; 95%CI: 1.56–5.26), and not received postnatal care services (AOR: 3.09; 95%CI: 1.73–5.51) were more likely to die. The odds of neonatal death was higher among neonates not breastfed within the first hour of delivery than those who breastfed within the first hour of delivery (AOR: 23.48; 95%CI: 8.43–65.37). Likewise, no-colostrum intake was positively associated with neonatal death. Neonates born to mothers who not received or received a single dose of tetanus toxoid injection (TTI) were more likely to experience death than those neonates born to mothers who received two or more doses of TTI (AOR: 2.05; 95%CI: 1.14–3.70). Furthermore, being small in size at birth (AOR: 2.66; 95%CI: 1.33–5.33) and male in sex (AOR: 1.85; 95% CI: 1.06–3.26) were risk factors for NM. In conclusion, neonatal mortality was significantly associated with factors that are modifiable through addressing the continuum-of-care approach in healthcare services in North Shoa. This implies that ensuring a continuity of health care services for maternal and new-borns from antenatal to postnatal care will improve neonatal survival.

Routine childhood vaccination is important to protect our children against ill health. Vaccines prevent up to 3 million deaths worldwide every year. After clean water, vaccination is the most effective public health intervention in the world for saving lives and promoting good health.Since vaccines were introduced in the UK, diseases like smallpox, polio and tetanus that used to kill or disable millions of people are either gone or seen very rarely. Other diseases like measles and diphtheria have been reduced by up to 99.9% since their vaccines were introduced. Vaccination is not compulsory, however, if people stop having vaccines, it's possible for infectious diseases to quickly spread again. The overall aim of the UK’s routine childhood immunisation schedule is to provide protection against the following vaccine-preventable infections:

Cervical cancer is the fourth most common cancer in women with an estimated 570,000 new cases in 2018 which constitute about 6. 6% of all cancers in women according to WHO report 2018. Approximately 90% of the 270,000 deaths from cervical cancer in 2015 occurred in low- and middle-income countries. In cervical cancers, which is caused by human papillomavirus (HPV) infection, the expression of HPV 16 E6 and E7 proteins are essential for tumor cell transformation and maintenance of malignancy. Prophylactic vaccines against cervical cancer caused by human papillomavirus have not proven successful. Although virus-like particle-based (VLPs) vaccines have been developed with prophylactic activities to prevent most HPV infections, the therapeutic effect of VLP vaccines has yet to be demonstrated for those who were already infected. A recent study showed that pre-conditioning mice with a potent antigen such as tetanus toxoid significantly improves lymph node homing and efficacy of dendritic cells. Tetanus toxoid has also been used in combination with DNA vaccines designed from tumor based antigens. In the present study, we pre-conditioned mice with tetanus toxoid followed by vaccination with a Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) overexpressing tumor-cell based vaccine (GVAX). We observed that pre-conditioning with tetanus toxoid followed by vaccination with GVAX regressed tumor growth and enhanced the overall survival of the mice. Pre-conditioning with tetanus toxoid enhanced the immune response which was observed by enlarged spleen size, higher proliferation rate of lymphocytes, a higher level of IFN-γ, TNF-α, and IL-4 antigen-specific secretions by the splenocytes. Pre-conditioning with tetanus toxoid increased memory T cell migration into the tumor site and spleen. The antigen-specific cytotoxic T cell lysis percentage was also found to be higher in the group of mice vaccinated with the combination of tetanus toxoid and GVAX. Hence, pre-conditioning with tetanus toxoid prior to vaccination with a tumor-cell based vaccine overexpressing GM-CSF might be an effective strategy for targeting E7-specific HPV-associated cervical malignancy.

Contains data from World Health Organization's data portal covering the following indicators:
Infant mortality rate (probability of dying between birth and age 1 per 1000 live births), Adolescent birth rate (per 1000 women aged 15-19 years), Contraceptive prevalence (%), Unmet need for family planning (%), Under-five mortality rate (probability of dying by age 5 per 1000 live births), Median availability of selected generic medicines (%) - Public, Median consumer price ratio of selected generic medicines - Public, Children aged <5 years sleeping under insecticide-treated nets (%), Children aged <5 years with fever who received treatment with any antimalarial (%), Prevalence of condom use by adults during higher-risk sex (15-49) (%), Deaths due to tuberculosis among HIV-negative people (per 100 000 population), Incidence of tuberculosis (per 100 000 population per year), Population aged 15-24 years with comprehensive correct knowledge of HIV/AIDS (%), Prevalence of tuberculosis (per 100 000 population), Births attended by skilled health personnel (%), Maternal mortality ratio (per 100 000 live births), Children aged <5 years stunted (%), Cholera - number of reported cases, Diphtheria - number of reported cases, Japanese encephalitis - number of reported cases, Pertussis - number of reported cases, Number of new leprosy cases, Total tetanus - number of reported cases, Meningitis - number of reported cases, Malaria - number of reported confirmed cases, Poliomyelitis - number of reported cases, Yellow fever - number of reported cases, H5N1 influenza - number of reported cases, Plague - number of reported cases, Mumps - number of reported cases, Congenital Rubella Syndrome - number of reported cases, Neonatal tetanus - number of reported cases, Rubella - number of reported cases, Measles - number of reported cases, Life expectancy at birth (years), Neonatal mortality rate (per 1000 live births), Low-birth-weight newborns (%), Children aged <5 years overweight (%), Alcohol consumption among adults aged ≥ 15 years (litres of pure alcohol per person per year), Literacy rate among adults aged >= 15 years (%), Population (in thousands) total, Population median age (years), Population proportion under 15 (%), Population living on <$1 (PPP int. $) a day (%), Civil registration coverage of births (%), Population proportion over 60 (%), Gross national income per capita (PPP int. $), Total fertility rate (per woman), Population living in urban areas (%), Annual population growth rate (%), Diphtheria tetanus toxoid and pertussis (DTP3) immunization coverage among 1-year-olds (%), Median availability of selected generic medicines (%) - Private, Hospital beds (per 10 000 population), Private prepaid plans as a percentage of private expenditure on health, Per capita government expenditure on health at average exchange rate (US$), Per capita total expenditure on health (PPP int. $), Children aged < 5 years with pneumonia symptoms taken to a healthcare provider (%), Children aged <5 years with diarrhoea receiving ORT (%), Per capita government expenditure on health (PPP int. $), Measles-containing-vaccine first-dose (MCV1) immunization coverage among 1-year-olds (%), Antenatal care coverage - at least one visit (%), General government expenditure on health as a percentage of total government expenditure, Births by caesarean section (%), Median consumer price ratio of selected generic medicines - Private, Hepatitis B (HepB3) immunization coverage among 1-year-olds (%), External resources for health as a percentage of total expenditure on health, Number of dentistry personnel, Children aged 6-59 months who received vitamin A supplementation (%), Physicians density (per 10 000 population), Number of nursing and midwifery personnel, Neonates protected at birth against neonatal tetanus (PAB) (%), Hib (Hib3) immunization coverage among 1-year-olds (%), Social security expenditure on health as a percentage of general government expenditure on health, Number of physicians, [Deaths due to HIV/AIDS (per 100